Products for Research Use Only
RegisterLogin

Ocrelizumab

CAT: 0804-HY-P9960-01Size: 1 mgDry Ice: YesHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P9960-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ocrelizumab (Ocrevus) is a humanized anti-CD20 monoclonal antibody. Ocrelizumab can induce B cell depletion and inhibit multiple sclerosis lesions in mice through antibody dependent cytotoxicity (ADCC) [1][2].
CAS Number
637334-45-3
Product Name Alternative
2H7; PRO70769; RG1594
UNSPSC
12352203
Target
CD20
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ocrelizumab.html
Purity
99.61
Solubility
H2O
Smiles
[Ocrelizumab]
Molecular Weight
(145.82 kDa)
References & Citations
[1]Torres JB, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration. Front Immunol. 2022 Jul 28;13:814064.|[2]Schubart A, et al. Effect of Subcutaneous vs Intravenous Chronic Treatment with an Anti-CD20 Antibody on B-, T-and Myeloid Lymphocyte Subsets in Blood, Lymph Nodes and Spleen of C57BL/6 Mice (P2. 410) [J]. Neurology, 2018, 90 (15_supplement) : P2. 410.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched

Alternative Products

CatalogName
CLA1174-01Ocrelizumab
CBA1066-01Ocrelizumab Biosimilar
GTR18578436-01Ocrelizumab Antibody
HY257026-01Research Grade Ocrelizumab
047968CD20 (ocrelizumab) discontinued
592058Ocrelizumab (MS4A1, CD20)
GTR18778072-01Ocrelizumab Neutralizing Antibody
E55A04062Ocrelizumab Polyclonal Antibody
C00352-1mg*25Ocrelizumab (Anti-CD20)
AY257038Ocrelizumab ELISA Kit

Popular Products